K. Schneck

发表

A 5‐week study of the pharmacokinetics and pharmacodynamics of LY2189265, a novel, long‐acting glucagon‐like peptide‐1 analogue, in patients with type 2 diabetes

T. Hardy, F. Tibaldi, J. Chien, 2011, Diabetes, obesity & metabolism.

Prediction of Renal Transporter Mediated Drug-Drug Interactions for Pemetrexed Using Physiologically Based Pharmacokinetic Modeling

Maria M. Posada, Stephen D. Hall, K. Hillgren, 2015, Drug Metabolism and Disposition.

LY2189265, a long‐acting glucagon‐like peptide‐1 analogue, showed a dose‐dependent effect on insulin secretion in healthy subjects

F. Tibaldi, J. Chien, P. Barrington, 2011, Diabetes, obesity & metabolism.

Pemetrexed Safety and Pharmacokinetics in Patients with Third-Space Fluid

L. Paz-Ares, J. Latz, J. Sørensen, 2010, Clinical Cancer Research.

Phase I and Pharmacokinetic Study of Pemetrexed with High-Dose Folic Acid Supplementation or Multivitamin Supplementation in Patients with Locally Advanced or Metastatic Cancer

A. Tolcher, C. Takimoto, M. Beeram, 2007, Clinical Cancer Research.

Metastatic Cancer Supplementation in Patients with Locally Advanced or High-Dose Folic Acid Supplementation or Multivitamin Phase I and Pharmacokinetic Study of Pemetrexed with

A. Tolcher, C. Takimoto, M. Beeram, 2007 .

Dose selection using a semi-mechanistic integrated glucose-insulin-glucagon model: designing phase 2 trials for a novel oral glucokinase activator

J. Bue-Valleskey, M. Heathman, K. Schneck, 2013, Journal of Pharmacokinetics and Pharmacodynamics.

Toward Better Understanding of Insulin Therapy by Translation of a PK‐PD Model to Visualize Insulin and Glucose Action Profiles

L. Tham, J. Reviriego, K. Schneck, 2018, Journal of clinical pharmacology.

Modeling Pharmacokinetic Profiles of Insulin Regimens to Enhance Understanding of Subcutaneous Insulin Regimens

L. Tham, J. Reviriego, K. Schneck, 2017, Journal of clinical pharmacology.

A phase I study of pemetrexed in patients with relapsed or refractory acute leukemia

H. Kantarjian, F. Ravandi, W. Plunkett, 2011, Investigational New Drugs.

Assessment of glycemic response to an oral glucokinase activator in a proof of concept study: application of a semi-mechanistic, integrated glucose-insulin-glucagon model

M. Karlsson, K. Schneck, V. Sinha, 2013, Journal of Pharmacokinetics and Pharmacodynamics.

Assessment of glycemic response to an oral glucokinase activator in a proof of concept study: application of a semi-mechanistic, integrated glucose-insulin-glucagon model

Mats O. Karlsson, Robert Bauer, M. Karlsson, 2012, Journal of Pharmacokinetics and Pharmacodynamics.